These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3280345)

  • 21. alpha-Methylproline-containing renin inhibitory peptides: in vivo evaluation in an anesthetized, ganglion-blocked, hog renin infused rat model.
    Thaisrivongs S; Pals DT; Lawson JA; Turner SR; Harris DW
    J Med Chem; 1987 Mar; 30(3):536-41. PubMed ID: 3546690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New human renin inhibitory peptides: angiotensinogen transition-state analogues containing novel Leu-Val replacement and a retro-inverso amide bond.
    Iizuka K; Kamijo T; Harada H; Akahane K; Kubota T; Shimaoka I; Umeyama H; Kiso Y
    Chem Pharm Bull (Tokyo); 1988 Jun; 36(6):2278-81. PubMed ID: 3071424
    [No Abstract]   [Full Text] [Related]  

  • 23. Renin inhibitors containing esters at the P2-position. Oral activity in a derivative of methyl aminomalonate.
    Repine JT; Himmelsbach RJ; Hodges JC; Kaltenbronn JS; Sircar I; Skeean RW; Brennan ST; Hurley TR; Lunney E; Humblet CC
    J Med Chem; 1991 Jul; 34(7):1935-43. PubMed ID: 2066966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renin inhibitors containing nicotinic or isonicotinic acid at the N-terminus. Part V.
    Paruszewski R; Jaworski P; Tautt J; Dudkiewicz J
    Boll Chim Farm; 1995 Nov; 134(10):551-6. PubMed ID: 8562014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renin inhibitors. Dipeptide analogues of angiotensinogen incorporating transition-state, nonpeptidic replacements at the scissile bond.
    Bolis G; Fung AK; Greer J; Kleinert HD; Marcotte PA; Perun TJ; Plattner JJ; Stein HH
    J Med Chem; 1987 Oct; 30(10):1729-37. PubMed ID: 3309313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonpeptide renin inhibitors employing a novel 3-aza(or oxa)-2,4-dialkyl glutaric acid moiety as a P2/P3 amide bond replacement.
    Baker WR; Fung AK; Kleinert HD; Stein HH; Plattner JJ; Armiger YL; Condon SL; Cohen J; Egan DA; Barlow JL
    J Med Chem; 1992 May; 35(10):1722-34. PubMed ID: 1588554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renin inhibitors. Design and synthesis of a new class of conformationally restricted analogues of angiotensinogen.
    Sham HL; Bolis G; Stein HH; Fesik SW; Marcotte PA; Plattner JJ; Rempel CA; Greer J
    J Med Chem; 1988 Feb; 31(2):284-95. PubMed ID: 3276890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological activity of some transition-state inhibitors of human renin.
    Bühlmayer P; Caselli A; Fuhrer W; Göschke R; Rasetti V; Rüeger H; Stanton JL; Criscione L; Wood JM
    J Med Chem; 1988 Sep; 31(9):1839-46. PubMed ID: 3137345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action.
    Rosenberg SH; Woods KW; Sham HL; Kleinert HD; Martin DL; Stein H; Cohen J; Egan DA; Bopp B; Merits I
    J Med Chem; 1990 Jul; 33(7):1962-9. PubMed ID: 2194033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [In vitro and in vivo inhibition of renin by a thiazolylalanyl cyclostatine derivative].
    Muneta S
    Nihon Jinzo Gakkai Shi; 1989 Aug; 31(8):865. PubMed ID: 2512401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel small renin inhibitors containing 4,5- or 3,5-dihydroxy-2-substituted-6-phenylhexanamide replacements at the P2-P3 sites.
    Jung GL; Anderson PC; Bailey M; Baillet M; Bantle GW; Berthiaume S; Lavallée P; Llinas-Brunet M; Thavonekham B; Thibeault D; Simoneau B
    Bioorg Med Chem; 1998 Dec; 6(12):2317-36. PubMed ID: 9925293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Difluorostatine- and difluorostatone-containing peptides as potent and specific renin inhibitors.
    Thaisrivongs S; Pals DT; Kati WM; Turner SR; Thomasco LM
    J Med Chem; 1985 Nov; 28(11):1553-5. PubMed ID: 3906126
    [No Abstract]   [Full Text] [Related]  

  • 33. Novel renin inhibitors containing analogues of statine retro-inverted at the C-termini: specificity at the P2 histidine site.
    Rosenberg SH; Plattner JJ; Woods KW; Stein HH; Marcotte PA; Cohen J; Perun TJ
    J Med Chem; 1987 Jul; 30(7):1224-8. PubMed ID: 3298652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renin inhibitory peptides. Incorporation of polar, hydrophilic end groups into an active renin inhibitory peptide template and their evaluation in a human renin infused rat model and in conscious sodium-depleted monkeys.
    Thaisrivongs S; Pals DT; DuCharme DW; Turner SR; DeGraaf GL; Lawson JA; Couch SJ; Williams MV
    J Med Chem; 1991 Feb; 34(2):633-42. PubMed ID: 1995887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors.
    Patt WC; Hamilton HW; Taylor MD; Ryan MJ; Taylor DG; Connolly CJ; Doherty AM; Klutchko SR; Sircar I; Steinbaugh BA
    J Med Chem; 1992 Jul; 35(14):2562-72. PubMed ID: 1635057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Substrate analogue renin inhibitors containing replacements of histidine in P2 or isosteres of the amide bond between P3 and P2 sites.
    Raddatz P; Jonczyk A; Schmitges CJ; Sombroek J
    Adv Exp Med Biol; 1991; 306():387-90. PubMed ID: 1812733
    [No Abstract]   [Full Text] [Related]  

  • 37. Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site.
    Rosenberg SH; Dellaria JF; Kempf DJ; Hutchins CW; Woods KW; Maki RG; de Lara E; Spina KP; Stein HH; Cohen J
    J Med Chem; 1990 Jun; 33(6):1582-90. PubMed ID: 2187994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New inhibitors of human renin that contain novel replacements at the P2 site.
    Doherty AM; Kaltenbronn JS; Hudspeth JP; Repine JT; Roark WH; Sircar I; Tinney FJ; Connolly CJ; Hodges JC; Taylor MD
    J Med Chem; 1991 Apr; 34(4):1258-71. PubMed ID: 1901910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. alpha-Hydroxy phosphinyl-based inhibitors of human renin.
    Patel DV; Rielly-Gauvin K; Ryono DE; Free CA; Rogers WL; Smith SA; DeForrest JM; Oehl RS; Petrillo EW
    J Med Chem; 1995 Oct; 38(22):4557-69. PubMed ID: 7473584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides.
    Rosenberg SH; Spina KP; Woods KW; Polakowski J; Martin DL; Yao Z; Stein HH; Cohen J; Barlow JL; Egan DA
    J Med Chem; 1993 Feb; 36(4):449-59. PubMed ID: 8474101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.